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SUMMARY – Th e purpose of this study was to analyze the possible prognostic value of RET 
mutation in papillary thyroid carcinoma and its incidence in the past few decades in our population, 
due to the increasing incidence of papillary thyroid carcinoma. Th e present study included 180 pa-
tients operated for papillary thyroid carcinoma. Th e clinical and histopathologic characteristics were 
analyzed. Paraffi  n sections of the selected histologic slides were cut again and immunohistochemi-
cally stained by the Clone 3F8 P (HIER) from Novocastra (Vision Bio Systems Europe, Newcastle 
upon Tyne, UK) monoclonal antibody to RET oncoprotein. Univariate analysis indicated sex (p=0.01), 
histologic subtype (p=0.075) and capsular invasion (p=0.010) to be statistically signifi cant predictors 
of lymph node metastases, whereas age (p=0.796), tumor size (p=0.556) and intraglandular dissemina-
tion (p=0.131) showed no such correlation. Th e presence of RET mutation (p=0.704) was not a statis-
tically signifi cant predictor of the tumor metastasizing potential. RET mutation (p=0.500) showed no 
statistically signifi cant correlation with papillary thyroid carcinoma classifed into prognostic groups 
according to clinicopathologic features either. RET mutation was detected in 30% of 180 papillary 
thyroid carcinomas. Th is is the fi rst large study demonstrating that RET mutation incidence in papil-
lary thyroid carcinoma in Croatian population is consistent with the classic distribution of sporadic 
cases, despite the increased prevalence of papillary thyroid carcinoma in the past few decades.
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Introduction
Rearrangement of the tyrosine kinase receptor 
gene (RET gene named RET/PTC) is the most com-
mon structural genetic alteration which, however, 
shows great geographical variability ranging from 0 to 
80% in diff erent studies1. In addition, BRAF point 
mutation, TRK gene rearrangement and RAS muta-
tion have been found in papillary carcinoma2-4.
RET proto-oncogene has been identifi ed in he-
reditary MEN2 syndrome, and is involved in sporadic 
medullary and papillary thyroid carcinoma (PTC) and 
Hirschsprung’s disease5. RET proto-oncogene is lo-
cated on the long arm of chromosome 10. Genetically 
activated RET rearrangements are implied in the 
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pathogenesis of PTC6. Variation in the prevalence of 
RET activation is believed to be attributable to diff er-
ent methods and sensitivity of the techniques used, 
and to environmental factors, ionizing radiation expo-
sure in particular1.
Th ere is no RET immunoreactivity in normal thy-
roid tissue7. Th e mean frequency of RET mutation in 
sporadic papillary carcinoma is 20%-30% in adults, 
rising up to 45%-50% in pediatric and young patients, 
and being highest (50%-80%) in patients with a his-
tory of accidental or therapeutic radiation exposure8-10. 
Accordingly, it appears quite reasonable to believe that 
the pathomorphologically identical papillary carcino-
mas must have followed diff erent routes of carcino-
genesis characterized by diff erent clinical manifesta-
tion. In the last decades, there was a signifi cant increase 
in the number of PTC, so one of the possibilities was 
the infl uence of radiation like that due to Chernobyl 
nuclear power plant disaster11. Knowing that RET 
mutation has been proven to be a good marker for its 
infl uence, we decided to analyze this relationship and 
to evaluate if there is increament in the RET mutation 
incidence following the rising PTC incidence9.
Patients and Methods
Patients
Th e present study included 180 PTC patients op-
erated between January 1, 1999 and December 31, 
2001 at ENT Department, Split University Hospital 
Centre in Split. Clinical data were collected from pa-
tient medical records from Department of Nuclear 
Medicine fi les and histology fi ndings from Depart-
ment of Pathology and Cytology database. Clinical 
and pathologic data were analyzed and classifi ed into 
two groups according to study criteria (age, sex, tumor 
size, histologic subtype, intraglandular dissemination, 
extrathyroid dissemination, and metastases): group 1 
with favorable prognosis (low risk) included patients 
aged <45, female, tumor size up to 2 cm, papillary and 
follicular subtype limited to the thyroid, no intraglan-
dular dissemination, and absence of metastases; and 
group 2 with poor prognosis (high risk) included all 
those that did not meet all group 1 criteria, i.e. age >45, 
male, tumor size exceeding 2 cm, all subtypes except 
for papillary and follicular ones, capsular invasion, in-
traglandular dissemination, and metastases to lymph 
nodes. At the time of the Chernobyl accident, 33% 
and 66% of patients were aged <30 and >30 years, re-
spectively.
Methods
Tissue for histologic analysis was obtained from 
operative material, fi xed in 4% buff ered formalin for 
24 h, paraffi  n embedded, cut into 3- to 5-m sections 
and stained by the standard hemalaun eosin method 
(HE). Paraffi  n sections of the selected histologic prep-
arations were cut again and immunohistochemically 
stained. Antigen retrieval was performed in 10 mM 
citrate buff er (pH 6.0) inside a microwave pressure 
cooker. Slides were immediately placed into a bath of 
tap water. Sections were washed in TBS buff er for 1x5 
minutes, then placed in diluted normal serum for 10 
minutes. Th en the slides were incubated with primary 
antibody. Th e Clone 3F8 P (HIER) from Novocastra 
(Vision Bio Systems Europe, Newcastle upon Tyne, 
UK) monoclonal antibody to RET oncoprotein was 
used, at 1:40 dilution. Th en the slides were washed in 
TBS buff er for 2x5 minutes, incubated in biotinylated 
secondary antibody, washed in TBS buff er for 2x5 
minutes again, incubated in ABC reagent, washed in 
TBS buff er for 2x5 once more, incubated in DAB and 
washed thoroughly in running tap water. Slides were 
counterstained in hematoxylin, dehydrated and 
mounted.
Th e presence of RET/PTC was determined by the 
presence of diff use cytoplasmic staining on the normal 
measuring scale (Fig. 1). Th e absence of staining indi-
Fig. 1. Diff use cytoplasmic staining indicates the presence 
of RET/PTC.
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cated absence of the study mutation. Small intestine 
ganglial cells were used as positive control12.
Statistics
Descriptive statistics was employed for distribution 
of data obtained in the patient sample, whereas Pear-
son’s 2-test, Fisher exact test and multivariate analysis 
of binary logistic regression were used on correlation 
of the results obtained. Th e level of statistical signifi -
cance was set at p<0.05.
Results
In the study population, patients aged >45 as an 
unfavorable prognostic factor prevailed, with a 2:1 
older to younger group ratio. Sex distribution of the 
study population showed as many as 79.4% of female 
patients, yielding a 1:3.8 male to female ratio.
According to the new TNM classifi cation, T1 tu-
mor has a borderline size of 2 cm, which was also ad-
opted in the present study. Using this size criterion, 
carcinomas of up to 2 cm in size predominated (n=130; 
72.2%). Based on the defi ned prognostic features of 
histologic subtypes and trying to facilitate analysis, 
papillary carcinomas were classifi ed into two catego-
ries of favorable and unfavorable subtypes.
Papillary and follicular subtypes were classifi ed 
into favorable category and accounted for as many as 
146 (81.1%) cases, whereas unfavorable category in-
cluded high cellular, diff usely sclerosing and oncocytic 
subtypes, found in 34 (18.9%) cases. Intraglandular 
dissemination (multifocality) was observed in 44.4% 
of study carcinomas. Current state-of-the-art indi-
cates capsular invasion as a defi nitely poor prognostic 
factor. Th is lesion was recorded in 28 (15.6%) and 
lymph node metastases in 38 (21.1%) carcinomas. Al-
though distant metastases from PTC are extremely 
rare, sporadic cases have been reported from similar 
large studies. In our study, however, distant metastases 
were not recorded at all. Analysis of immunohisto-
chemical staining for RET mutation revealed its pres-
ence in 57 (31.7%) patients (Table 1).
Analyzing particular characteristics of papillary 
carcinoma in our patients, we assessed the impact of 
each clinical and histologic feature on the presence of 
metastases. Patient age had no eff ect on the prevalence 
of metastases, as indicated by the results of 2-test 
(p=0.796) and Fisher exact test (p=0.849) (Table 2).
Metastases to lymph nodes were detected in 25 of 
143 female patients and 13 of 37 male patients. Results 
of 2-test (p=0.019) and Fisher exact test (p=0.025) re-
vealed the prevalence of metastases to be statistically 
signifi cantly higher in male patients (Table 2).
Considering the borderline tumor size of 2 cm, the 
ratio of non-metastasizing to metastasizing tumors 
was 104:26 in the <2 cm group and 38:12 in the >2 cm 
group. Results of 2-test (p=0.556) and Fisher exact 
test (p=0.547) showed that tumor size had no statisti-














































































a2-test p=0.796; Fisher exact test p=0.849; b2-test p=0.019; Fisher 
exact test p=0.025; c2-test p=0.556; Fisher exact test p=0.547; 
d2-test p=0.075; Fisher exact test p=0.101; e2-test p=0.131; Fisher 
exact test p=0.145; f2-test p=0.010; Fisher exact test p=0.021; 
g2-test p=0.704; Fisher exact test p=0.699
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cally signifi cant impact on the occurrence of metasta-
ses (Table 2).
Division of PTCs into favorable and unfavorable 
subtypes revealed the presence of metastasizing poten-
tial in 27 of 146 and 11 of 34 patients, respectively. Th e 
2-test (p=0.075) and Fisher exact test (p=0.101) 
yielded a statistically signifi cantly greater rate of me-
tastases in the group of unfavorable subtypes (Table 2).
Th ere was no statistically signifi cant diff erence in 
the prevalence of metastases according to the presence 
of intraglandular dissemination (multifocality) (2-
test: p=0.131; Fisher exact test: p=0.145) (Table 2).
Metastases were detected in 27 of 152 cases of 
PTC without capsular invasion and in as many as 11 
of 28 cases with capsular invasion, yielding a statisti-
cally signifi cant between-group diff erence (2-test: 
p=0.010; Fisher exact test: p=0.021). Accordingly, the 
prevalence of metastases was infl uenced by the pres-
ence of capsular invasion (Table 2).
Th ere was no statistically signifi cant diff erence in 
the prevalence of metastases according to the presence 
or absence of RET mutation as the mechanism of car-
cinogenesis (2-test: p=0.704; Fisher exact test: 
p=0.699) (Table 2).
According to the set criteria for good and poor 
prognosis, 21 PTC cases met all the criteria for good 
prognosis, whereas 159 high-risk cases were associated 
with poor prognosis.
Th ere was no statistically signifi cant diff erence in 
the frequency of RET mutation as the mechanism of 
carcinogenesis between the two prognostic groups of 
PTC patients (2-test: p=0.500; Fisher exact test: 
p=0.618) (Table 3).
Univariate analysis was followed by multivariate 
analysis of the PTC characteristics according to the 
occurrence of metastases.
Binary logistic regression identifi ed two variables 
that statistically signifi cantly infl uenced the occur-
rence of metastases, i.e. male sex associated with a 
2.409 risk of metastases recorded in female patients 
(p=0.058) and capsular invasion associated with a 
2.519 risk of metastases found in patients free from 
invasion (p=0.083) (Table 4).
Discussion
Immunohistochemical methods of staining that 
enable detection of specifi c markers of particular cell 
types of normal and tumor tissue have found applica-
tion in the diagnosis of thyroid carcinomas. It is known 
that no RET immunoreactivity is found in normal 
thyroid tissue7. In the pathogenesis of PTC, RET ac-
tivation is frequently induced by radiation, mostly at 
younger age but also in adults11-13 . RET mutation ac-
counts for 20%-30% of sporadic papillary carcinomas 
in adults, 45%-50% in children and adolescents, and 
50%-80% in patients with a history of accidental or 
therapeutic radiation exposure8-10. In our study popu-
lation, RET mutation was detected in 57 (31.7%) pa-
tients (Table 1), which is consistent with most studies 
on sporadic papillary carcinoma. Th ese results con-
fi rmed our hypothesis that radiation exposure like the 
one caused by Chernobyl disaster did not contribute to 
the increased incidence of papillary carcinoma in the 
population.
Investigating the incidence of PTC during the last 
four decades, Jung et al. found that the proportion of 
Table 3. Immunoreactivity to RET mutation in low- 







































2-test p=0.500; Fisher exact test p=0.618
Table 4. Multivariate analysis of lymph node metastasis 
predictors in thyroid papillary carcinoma
Variable Signifi cance Odds ratio
Age (yrs) 0.384 0.660
Sex (male/female) 0.058 2.409
Tumor size 0.366 0.648
Tumor subtype 0.569 1.343
Intraglandular dissemination 0.301 1.556
Capsular invasion 0.083 2.519
RET 0.828 1.102
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RET/PTC rearrangements decreased, so the increased 
incidence of PTC was not due to environmental or 
therapeutic radiation15.
Analysis of correlation between the classic param-
eters of PTC and their metastasizing potential re-
vealed sex, tumor size, carcinoma variant and capsular 
invasion to infl uence the occurrence of metastases, 
whereas age and multifocality had no statistically sig-
nifi cant impact on the tumor metastasizing potential 
(Table 2). Th ese results are consistent with the current 
state-of-the-art on the role of these pathologic and 
clinical characteristics in papillary carcinoma2, thus 
our study group represented an appropriate model for 
additional analyses.
Analyzing the correlation between RET mutation 
and classic prognostic parameters in papillary carci-
noma, some authors demonstrated RET mutation to 
be present at a higher frequency in small, slow pro-
gressing and less aggressive tumors, and conclude that 
it may serve as a favorable marker in these tumors16,17. 
Th is is supported by Sugg et al., who identifi ed this 
mutation mostly in occult microcarcinomas18. An op-
posite concept has been proposed by Miki et al., based 
on the fi nding of higher RET expression in association 
with extrathyroid tumor invasion19.
Sassolas et al. report similar results in a population 
of young adults, where the presence of RET/PTC (1 
and 3) was associated with histologic and clinical 
short-therm aggressiveness, but no such relationship 
was found in children and adolescents20.
In the present study, RET association with papil-
lary carcinomas divided into prognostic categories 
(Table 3) according to the classic clinical and patho-
logic parameters was investigated. Categorization into 
prognostic groups by use of very strict criteria for fa-
vorable prognosis (low-risk group): age <45, female 
sex, tumor size up to 2 cm, papillary or follicular vari-
ant confi ned to the thyroid, no intraglandular dissemi-
nation, and no metastases; and poor prognosis (high-
risk group): those not meeting all the former group 
criteria, showed as many as 88.3% of study patients to 
belong to the high-risk group, thus highlighting the 
possible factors for poor prognosis. However, there was 
no statistically signifi cant diff erence in the prevalence 
of RET mutation between these prognostic groups of 
PTC patients (2-test: p=0.500; Fisher exact test: 
p=0.618) (Table 3). Th is fi nding is highly comparable 
with the report by Shin et al. on the association of 
RET expression with the clinicopathologic parameters 
of age, sex, tumor size, intraglandular dissemination, 
lymph node metastases and extrathyroid invasion14.
Th e researchers investigating the post-Chernobyl 
prevalence of papillary carcinoma in Ukraine and in 
young population exposed to therapeutic irradiation in 
childhood found a high percentage of RET mutation 
associated with an increased rate of lymph node me-
tastases7,9,21. In contrast, Collins et al. found the asso-
ciation of young age and lymph node metastases to be 
more pronounced in the group of patients without a 
history of radiation exposure. In their study, age diff er-
ence between patients with and without lymph node 
involvement was only recorded in the group of patients 
without a history of radiation exposure, thus the in-
creased prevalence of metastases could be directly re-
lated to younger age7. Th e association between RET 
mutation and metastasizing potential has been investi-
gated in many studies. Jhiang et al. suggest that RET 
might also be associated with distant metastases in 
sporadic cases22, while Mayr et al. postulate it to cor-
relate with early dissemination to lymph nodes23, 
which is less probable in case of distant metastases.
More recent results reveal connection of a higher 
rate of RAS mutation with the less aggressive nature 
of encapsulated follicular variant of PTC, which dif-
fers from the more aggressive infi ltrative follicular 
variant, whereas opposite holds for the BRAF muta-
tion pattern24.
In our study, there was no association of RET mu-
tation with lymph node metastases, thus there was no 
statistically signifi cant diff erence in the prevalence of 
metastases according to the presence or absence of 
RET mutation as the mechanism of carcinogenesis 
(2-test: p=0.704; Fisher exact test: p=0.699) (Table 2). 
Th e more so, RET mutation was the fi rst parameter 
excluded by the stepwise method, implying its lowest 
possible impact (Table 4).
Considering obvious variation in the results re-
ported from diff erent studies including ours, it appears 
quite reasonable to presume that some other factors 
may also infl uence the prognostic signifi cance of RET 
mutation. Also, contribution to the increased inci-
dence of papillary carcinoma in our population is 
probabbly due to diff erent factors such as better diag-
nostic procedures and more sophisticated medical 
technology.
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Sažetak
UČESTALOST RET MUTACIJE U PAPILARNOM KARCINOMU ŠTITNJAČE 
I KORELACIJA S KLINIČKO-PATOLOŠKIM KARAKTERISTIKAMA
A. Punda, V. Bedeković, A. Barić, M. Kontić, Z. Čolović, L. Vanjaka Rogošić, H. Punda, 
N. Kunac, L. Grandić i V. Pešutić Pisac
Cilj ovoga rada bio je ispitati moguće prognostičko značenje RET mutacije u papilarnom karcinomu štitnjače i učestalost 
mutacije u odnosu na porast učestalosti papilarnog karcinoma štitnjače u posljednjih nekoliko desetljeća. U istraživanje je bilo 
uključeno 180 bolesnika operiranih zbog papilarnog karcinoma štitnjače. Analizirane su kliničke i patohistološke osobitosti. 
Histološki rezovi iz parafi nskih blokova odabranih uzoraka imunohistokemijski su obojani monoklonskim protutijelom na 
RET onkoprotein Clone 3F8 P (HIER) proizvođača Novocastra (Vision Bio Systems Europe, Newcastle upon Tyne, UK). 
Univarijatnom analizom utvrđena je statistički značajna povezanost spola (p=0,01), histološkog podtipa (p=0,075) i kapsu-
larne invazije (p=0,010) kao prediktora pojave metastaza u limfne čvorove vrata, dok takva povezanost nije zabilježena za dob 
(p=0,796), veličinu tumora (p=0,556) i intraglandularnu diseminaciju tumora (p=0,131). Prisutnost RET mutacije nije bila 
statistički značajan prediktor metastatskog potencijala tumora (p=0,704). Također, RET mutacija nije bila statistički značaj-
no povezana s prognostičkim skupinama papilarnog karcinoma koje su sastavljene na temelju kliničko-patološkh osobitosti 
(p=0,500). RET mutacija bila je prisutna u 30% od 180 papilarnih karcinoma štitnjače. Ovo je prvo veće istraživanje kojim 
je dokazano da je RET mutacija u papilarnom karcinomu štitnjače u Hrvatskoj u skladu s učestalošću pojave spontane 
 mutacije, iako se bilježi porast učestalosti papilarnog karcinoma štitnjače tijekom posljednjih desetljeća.
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